Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07 2022 - 8:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that Stephen R. Brady, chief executive officer of
Tempest, will present at the H.C. Wainwright 24th Annual Global
Investment Conference. The company presentation will be available
for on-demand viewing Monday, September 12, 2022, at 7:00 a.m. ET
on the investor section of the Tempest website at
https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both programs are advancing through clinical
trials designed to study the agents as monotherapies and in
combination with other approved agents. Tempest is also developing
an orally available inhibitor of TREX-1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
South San Francisco. More information about Tempest can be found on
the company’s website at www.tempesttx.com.
Investor Contacts:Sylvia WheelerWheelhouse Life
Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2023 to Jul 2024